Subscribe
Be the first with the news that moves the market- Innocan Pharma’s (INNO) controlled efficacy test of its vaginal derma product containing cannabinoids, phytoestrogens, hyaluronic acid, and probiotics yielded successful results, reducing symptoms and improving overall vaginal health
- The 56-day trial involved a group of female volunteers with symptoms of vaginal discomfort
- The product achieved statistically significant results after 28 days of use, including improvements in vaginal burning, itching, dryness, pain during intercourse, and urinary discomfort
- Innocan’s vaginal derma product offers a natural and healthy alternative to traditional treatments containing hormones or steroids, which can have negative side effects
- Innocan is a pharmaceutical technology company that focuses on developing innovative drug delivery platform technologies with cannabinoid science
- Innocan Pharma (INNO) opened today at $0.25
Innocan Pharma (INNO) has announced successful results from a controlled efficacy test of its vaginal derma product.
The 56-day trial was conducted with a group of female volunteers experiencing symptoms of vaginal discomfort.
The product, which contains cannabinoids, phytoestrogens, hyaluronic acid, and probiotics, was found to be effective in reducing symptoms, including vaginal burning, itching, dryness, pain during intercourse, and urinary discomfort.
In addition to alleviating symptoms, the product was reported to have other positive effects on vaginal health, including increased elasticity, better sensation during intimate relationships, and improved skin health.
The product does not contain hormones or steroids, which are commonly used to treat similar symptoms but can have negative side effects.
Innocan is a pharmaceutical technology company that focuses on developing innovative drug delivery platform technologies with cannabinoid science.
Innocan Pharma (INNO) opened today at $0.25.
